Entrada Therapeutics, Inc.
TRDA Healthcare Biotechnology
Entrada Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $25.4 million, down 87.9% from fiscal 2024. In the quarter to June 2026, revenue fell 54.0%, EPS grew 2.88% and free cash flow fell 9.10%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow TRDA
Entrada Therapeutics, Inc. (TRDA) P/E ratio
Entrada Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 23.5× (June 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 8.7× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 10 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TRDA Entrada Therapeutics, Inc. | n/m |
| ELDN Eledon Pharmaceuticals, Inc. compare | n/m |
| BCYC Bicycle Therapeutics PLC Sponsored ADR compare | n/m |
| ADCT ADC Therapeutics SA compare | n/m |
| UPB Upstream Bio, Inc. compare | n/m |
| ACOG Alpha Cognition Inc. compare | n/m |
| SION Sionna Therapeutics, Inc. compare | n/m |
| YARW Yarrow Bioscience, Inc compare | n/m |
| STRO Sutro Biopharma, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)